Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

被引:45
|
作者
Zabolotny, BP [1 ]
Zalai, CV [1 ]
Meterissian, SH [1 ]
机构
[1] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Surg Oncol, Montreal, PQ H3A 1A1, Canada
关键词
male breast neoplasms; aromatase inhibitors;
D O I
10.1002/jso.20233
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Male breast cancer is an uncommon occurrence. Treatment of male breast cancer is typically extrapolated from data on the treatment of female breast cancer. Recently, aromatase inhibition has been proven as an effective therapy for female breast cancer, particularly in the setting of advanced cancers. The efficacy of aromatase inhibitors in males, however, has not been established. We report the successful treatment of a male with locally advanced breast cancer using the aromatase inhibitor letrozole. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 50 条
  • [31] Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
    Christine Y. Lu
    Fang Zhang
    Anita K. Wagner
    Larissa Nekhlyudov
    Craig C. Earle
    Matthew Callahan
    Robert LeCates
    Xin Xu
    Dennis Ross-Degnan
    J. Frank Wharam
    Breast Cancer Research and Treatment, 2018, 171 : 235 - 242
  • [32] Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer
    Nabholtz, Jean-Marc
    Mouret-Reynier, Marie-Ange
    Durando, Xavier
    Van Praagh, Isabelle
    Al-Sukhun, Sana
    Ferriere, Jean-Pierre
    Choller, Philippe
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (09) : 1435 - 1447
  • [33] Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness
    Patel, Jankiben R.
    Gallegos, Karen M.
    Walker, Rashidra R.
    Davidson, A. Michael
    Davenport, Ian
    Tilghman, Syreeta L.
    ONCOLOGY LETTERS, 2021, 22 (02)
  • [34] Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
    Lu, Christine Y.
    Zhang, Fang
    Wagner, Anita K.
    Nekhlyudov, Larissa
    Earle, Craig C.
    Callahan, Matthew
    LeCates, Robert
    Xu, Xin
    Ross-Degnan, Dennis
    Wharam, J. Frank
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 235 - 242
  • [35] Male Breast Cancer as a Second Primary Cancer: Increased Risk Following Lymphoma
    Farr, Deborah E.
    Thomas, Alexandra
    Khan, Seema Ahsan
    Schroeder, Mary C.
    ONCOLOGIST, 2017, 22 (08) : 895 - 900
  • [36] Adjuvant hormonal therapy in peri- and postmenopausal breast cancer
    Ryan, Paula D.
    Goss, Paul E.
    ONCOLOGIST, 2006, 11 (07) : 718 - 731
  • [37] Poor persistence with hormonal therapy among women with breast cancer
    Bychkovsky, Brittany L.
    Schonberg, Mara A.
    JOURNAL OF GERIATRIC ONCOLOGY, 2016, 7 (03) : 154 - 157
  • [38] Adjuvant Hormonal Therapy for Early-Stage Breast Cancer
    Burstein, Harold J.
    Griggs, Jennifer J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 639 - +
  • [39] Risk of perioperative hormonal breast cancer therapy for microvascular flap complications in breast reconstruction
    Mahrhofer, Maximilian
    Reichert, Raphael
    Siegwart, Laura Cosima
    Russe, Elisabeth
    Schoeller, Thomas
    Wechselberger, Gottfried
    Weitgasser, Laurenz
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2023, 85 : 143 - 148
  • [40] Clinical characteristics of male patients with breast cancer in the Latino population
    Gonzalez-Nunez, Carlos
    Mohar, Alejandro
    Reynoso-Noveron, Nancy
    Alvarez-Gomez, Rosa Maria
    Chavarri-Guerra, Yanin
    Aguilar-Villanueva, Sergio
    Guzman-Trigueros, Raul
    Velazquez-Martinez, Areli
    Wegman-Ostrosky, Talia
    Porras-Reyes, Fanny
    Garcilazo, Alexandra
    Arce, Claudia
    Bargallo-Rocha, Juan Enrique
    Cabrera-Galeana, Paula
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (03) : 629 - 635